At Advisory Committee, Replimune Counters FDA Efficacy Doubts with Robust 3-Year Survival Data for RP1 in Advanced Melanoma
REPL has more than doubled off its 52-week low of $1.5 on elevated volume (2.4× avg).
Summary
At today's FDA advisory committee meeting, Replimune presented new 3-year survival and durability data for RP1, rebutting staff efficacy concerns and arguing for accelerated approval in advanced melanoma. The outcome is pivotal for the company, which faces a going concern warning and limited cash runway.
Key Events · Product Development and Regulatory · REPL
-
Advisory Committee Presentation Filed
Replimune filed its presentation for today's FDA advisory committee meeting on RP1 for advanced melanoma, disclosing new 3-year overall survival data (47.8% OS rate) and durable responses (median DOR 24.8 months).
-
Rebuttal to FDA Efficacy Concerns
The presentation directly addresses FDA staff concerns raised on July 28, arguing that the 33.6% ORR is nearly 5x the expected response for further anti-PD-1 therapy and that RECIST 1.1 analysis should include injected lesions given RP1's dual mechanism of action.
-
Favorable Safety Profile Highlighted
Safety data show mainly Grade 1-2 adverse events, no treatment-related Grade 5 events, and a discontinuation rate of only 7.9%, positioning RP1 as a safer alternative to the approved lifileucel regimen which carries a 7.5% treatment-related mortality.
-
Pivotal Regulatory Catalyst
Today's advisory committee vote is a make-or-break event for Replimune, which has a going concern warning and cash runway only into Q1 2027; a positive vote would significantly de-risk the BLA and improve financing prospects.
Analysis · REPL · Life Sciences
Today, Replimune is presenting its case to the FDA advisory committee for accelerated approval of RP1 in advanced melanoma. The presentation unveils new 3-year overall survival data—a 47.8% OS rate—and durable responses with a median DOR of 24.8 months, directly challenging the efficacy concerns raised by FDA staff just two days ago. The company contends that its 33.6% ORR is nearly five times the expected response for further anti-PD-1 therapy, while also emphasizing a favorable safety profile that includes no treatment-related Grade 5 events. With a going concern warning and cash runway extending only into Q1 2027, a positive committee vote is critical for the company's survival and would validate the drug's approvability ahead of the FDA's target action date.
At the time of this filing, REPL was trading at $5.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $454.2M. The 52-week trading range was $1.50 to $12.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.